Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes & cardiovascular risk: the risk: benefit seesaw

June 24th 2013

Whilst lifestyle changes are the cornerstone of diabetes treatment, pharmacological therapies are usually required, not just for glycaemic control but also for cardiovascular risk management. Although therapies are launched following evidence that they show benefit to a particular facet of diabetes management (often marginal), their use in the real world often throws up major issues. These have included the impact of thiazolidendiones on CV risk, bladder malignancy and fractures, the impact of drugs acting on the GLP-1 pathway and pancreatitis and the potential link between insulin glargine and cancer (eventually dispelled). These post marketing complications only serve to cause concern to both patients and clinicians.

Whilst these concerns focus on patients who have been diagnosed with diabetes, what about the increasing number of drugs which are now linked to its development. To corticosteroids, thiazide diuretics, Beta blockers and newer anti-psychotic agents do we now need to add that cornerstone of cardiovascular protection – the statin. This issue has once again come to prominence following the publication of a population based study in the BMJ. In this study, compared with the older agent Pravastatin, an increased risk of developing diabetes was noted in those patients on more potent statins especially Simvastatin and Atorvastatin. With Rosuvastatin, an increased risk became non-significant when dose was corrected for. It is worth pointing out that the patients who are prescribed statins due to their CV risk are those at higher risk of developing diabetes in the first place and that other risk factors were not corrected for in this study. This study is in keeping with an earlier meta-analysis of 13 trials which showed a 9% increased risk of diabetes after 4 years of treatment.

Most clinicians are well aware that all drugs have side effects which must be taken into account when considering the benefits. In those patients at high risk of developing diabetes other agents exist – for example thiazides in the treatment of hypertension. However, with the use of beta blockers and especially statins to treat ischaemic heart disease, the benefits of such treatment clearly outweighs any potential risk of diabetes. In those patients with established diabetes, the impact of a marginal deterioration of glycaemic control is tiny given the benefit of these agents.

So how should this all be translated into clinical practice? Patients are increasingly knowledgeable and concerned about their conditions and potential treatments, a situation sometimes magnified by the media. Ideally this should translate into a more balanced discussion with patients as to risk/ benefit of any agent – easier said than done in a service increasingly time pressured.

Dr. Mark Freeman

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Napp DiabetesAstraZenecaBoehringer IngelheimNovo Nordisk

Silver Sponsors

Abbott Diabetes CareAbout Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership